Sign in →

Test Code LAB4410 NAbFeron (IFNB-1) Neutralizing Antibody Test

Additional Codes

 

Test Name in EPIC EPIC Test Code Mnemonic Mayo Test ID
INTERFERON NEUTRAL AB LAB4410 NAB FINA

 

Reporting Name

NAbFeron (IFN-B) Antibody

Useful For

Detection of antibodies to interferon-B-1

Method Name

Viral cytopathic effect assay

Performing Laboratory

Athena Diagnostics

Specimen Type

Serum


Specimen Required


Specimen Type: Serum

Container/Tube: Red or SST

Specimen Volume: 2 mL

 

Collection Instructions: Draw blood in a plain red-top tube(s), serum gel tube is acceptable. Spin down and send 2 mL of serum refrigerate in a plastic vial.

 

Note: Sample needs to be collected either before treatment with interferon or more than 24 hours following the most recent dose. Patient should not be on steroid therapy for at least two weeks prior to testing.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  180 days
  Ambient  72 hours

Reject Due To

Hemolysis

NA

Thawing

NA

Lipemia

NA

Icterus

NA

Other

NA

Reference Values

Final report has been sent to the referring laboratory.

Day(s) and Time(s) Performed

Monday through Friday

CPT Code Information

86382

LOINC Code Information

Test ID Test Order Name Order LOINC Value
FINA NAbFeron (IFN-B) Antibody In Process

 

Result ID Test Result Name Result LOINC Value
Z0083 NAbFeron (IFN-B) Antibody In Process

Analytic Time

14 - 21 days

Test Classification

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. .

Cautions

The present of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with reduction in the clinical effectiveness of interferon beta therapy (1). Although the measurement of Nabs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history (2, 3).

 

Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.